Medical device and MedTech insights, news, tips and more

Jury Levels $1B Verdict Against J&J’s DePuy Ortho in Pinnacle Hip Bellwether

December 5, 2016


DePuyUPDATED Dec. 2, 2016, with quotes from plaintiff’s and defense attorneys and DePuy Orthopedics.

A federal jury in Dallas today ordered Johnson & Johnson (NYSE:JNJ) and its subsidiary DePuy Orthopedics to pay more than $1 billion to 6 plaintiffs claiming to be injured by its Pinnacle metal-on-metal hip implants, according to the plaintiffs lawyers.

Jurors in the case found that the metal-on-metal pinnacle hip implants were designed defectively and that the companies failed to appropriately warn patients of the risks associated with the devices. Plaintiff’s lawyer Mark Lanier said the $1.041 billion verdict included $32 million in compensatory damages and the remainder in punitive damages.

The New Brunswick, N.J.-based health products giant, which faces roughly 8,400 lawsuits over the hip implants, said it’s planning to immediately appeal the verdict and is committed to defending itself and DePuy from further litigation over the Pinnacle devices. Test cases in the MDL are being selected for trial; their outcomes will influence the course of the remaining suits.

Plaintiffs in the case, 6 California residents implanted with the Pinnacle devices, claimed they experienced tissue death, bone erosion and other injuries as a result of the design flaws. The individuals also claimed that the devices were promoted as longer laster than ceramic or plastic material devices.

DePuyLanier, who told Reuters that J&J rejected a $1.8 million settlement offer before the trial, said yesterday’s verdict was “a message loud and clear” that J&J has “a really nasty part of their business they need to clean up.”

Johnson & Johnson criticized the trial judge on rulings it claimed help the plaintiffs.

“Today’s verdict provides no guidance on the merits of the overall Pinnacle litigation because the court’s rulings precluded a fair presentation to the jury,” J&J attorney John Beisner said in a prepared statement, adding that the company plans to ask an appeals court to table any pending trials in the MDL.

“We have no greater responsibility than to the patients who use our products, and our goal is to create medical innovations that help people live more active and comfortable lives. DePuy acted appropriately and responsibly in the design and testing of [Pinnacle] metal-on-metal, and the product is backed by a strong track record of clinical data showing reduced pain and restored mobility for patients suffering from chronic hip pain,” DePuy spokesperson Mindy Tinsley said in prepared remarks.

In July, J&J and DePuy Orthopedics asked a federal appeals court this week to expedite the appeal of its $151 million loss in a product liability lawsuit brought over its Pinnacle metal-on-metal hip implant.

In March, a Texas federal jury slapped DePuy Orthopaedics with a $500 million judgment in favor of a quintet of plaintiffs who blamed the Pinnacle implant for their injuries. After a 2-month trial, jurors found that the Ultamet metal-on-metal version of the Pinnacle hips were defectively designed and that DePuy failed to warn patients about the risks, awarding $130 million in total compensatory damages and $360 million in punitive damages. DePuy won the 1st bellwether trial in the MDL, in October 2014. The judge in the case in July slashed the award to roughly $151 million.

Read Full Article – Source: Jury levels $1B verdict against J&J’s DePuy Ortho in Pinnacle hip bellwether – MassDevice

Author – 

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.